Second chance for hepatitis c cure: new trial tests best retreatment
NCT ID NCT05248919
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people in Pakistan with hepatitis C who did not get cured by their first treatment. It compares two different lengths of treatment with the drug Epclusa (12 weeks vs 24 weeks) to see which works better. About 318 adults will take part, and the goal is to find the safest and most effective way to clear the virus in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sofosbuvir and Velpatasvir (Epclusa)
What this could lead to
If successful, this trial could identify the best retreatment strategy for people with hepatitis C who did not get cured by first-line therapy, potentially improving cure rates in this group.
What could go wrong
This is a relatively small, non-randomized study in one region of Pakistan, so results may not apply broadly. The treatments are already approved, so the main question is which duration works best, not a breakthrough.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical trials unit
Karachi, Sindh, Pakistan